AccuMetab™ Human UGT1A9 Enzyme, Catalytically Active

CAT#: ITS-0426-YL96
Product Type: Recombinant Phase II Metabolizing Enzyme
Brand: AccuMetab
Development Stage: ADME
ADME Research Domain: Metabolism
Short Description
Human UGT1A9 for precise Phase II glucuronidation ADME screening.
Brand
AccuMetab
Development Stage
ADME
ADME Research Domain
Metabolism
Background
Highly expressed in the human liver and kidneys, UGT1A9 is a major workhorse enzyme responsible for the clearance of bulky phenols, NSAIDs, and propofol. Investigating UGT1A9 metabolism is essential for determining renal clearance pathways and predicting severe drug-drug interactions.
Key Features
High-activity Sf9 insect cell microsome format; Determines renal clearance pathways for bulky phenols; Critical for predicting propofol/NSAID interactions; Requires UDPGA cofactor for assay initiation
Applications
Phase II Drug Metabolism, Glucuronidation Studies
Research Areas
ADME; Phase II Conjugation
Species
Human
Expression System
Recombinant enzymes are prepared from baculovirus-infected Sf9 insect cells.
Physical Form
Liquid
Size
2.5 mg
Storage
-80°C
Storage Comment
When stored at -80°C, our product remains stable and retains full functional activity for up to 10 years.
Note
For bulk pricing or custom reagent inquiries, please contact us by email or phone. Products are shipped on ice via FedEx.
Restrictions
For Research Use Only (RUO). Not intended for diagnostic or therapeutic use.
Shipping
Our enzyme products are shipped at -80°C.
For Research Use Only | Not For Clinical Use
Online Inquiry